IL2RA and systemic sclerosis: To assess the relevance of IL-2R regulation of CEACAM1 in vivo, we examined the expression of CEACAM1 upon low-dose IL-2 therapy in 27 patients with 8 autoimmune diseases, i.e., systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, Crohn’s disease (CD), sclerosing cholangitis (SC), ankylosing spondylitis, Sjögren’s syndrome, and systemic sclerosis (SSc) (32).